Metyrapone/Oxazepam

Embera NeuroTherapeutics’ Chief Medical Officer, Michael Detke, to Moderate Panel on the Neuroscience of Addiction at BIO CEO & Investor Conference BOSTON, Mass. and SHREVEPORT, La. – February 12, 2018 – Embera NeuroTherapeutics today announced that Michael Detke, M.D., Ph.D., Embera’s Chief Medical Officer, will moderate the “Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis” panel at 2018 BIO CEO & Investor Conference. About EMB-001 EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by cues that contribute to the acquisition and maintenance of addiction. EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy as well as minimizing safety and tolerability concerns. Therapies that reduce cravings and relapse and thus result in long-term abstinence and recovery would be significant contributions to the treatment of a broad range of addictions. About Embera NeuroTherapeutics Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating a broad range of addictions where the major clinical challenge is a limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com Contacts Bob Linke President and CEO Embera NeuroTherapeutics, Inc. 617-719-9406 rlinke@emberaneuro.com For Media: MacDougall Biomedical Communications Kari Watson or Kara Mazey, 781-235-3060 kwatson@macbiocom.com kmazey@macbiocom.com ###

Embera NeuroTherapeutics to Present at the 10th Annual Biotech Showcase BOSTON, Mass. and SHREVEPORT, La. – July, 26, 2016 – December 12, 2017 – Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that Robert (Bob) Linke, the Company’s President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will present at the 10th Annual Biotech Showcase on Monday, January 8, 2018 at 10:00 a.m. Pacific time. The conference is being held from January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California. “Embera has a tremendous opportunity to further the development of EMB-001 into Phase 2 clinical trials in cocaine use disorder and tobacco use disorder. We are pleased with the opportunity to present at the Biotech Showcase to educate new audiences about our company and our lead candidate EMB-001 and its novel approach to addressing stress mediated diseases,” said Bob Linke. About Embera NeuroTherapeutics Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on stress modulation as an innovative way of treating a broad range of addictions and other diseases where there are significant public health impacts and a very limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com Contacts Bob Linke President and CEO Embera NeuroTherapeutics, Inc. 617-719-9406 rlinke@emberaneuro.com For Media: MacDougall Biomedical Communications Kari Watson or Kara Mazey, 781-235-3060 kwatson@macbiocom.com kmazey@macbiocom.com ###